After Aducanumab: Finding New Treatments For Neurodegenerative Diseases
An Interview With Rising Leader Virginie Buggia-Prevot
Executive Summary
As a freshman interested in neurobiology at Joseph Fourier University in Grenoble, Virginie Buggia-Prevot knocked on the lab door of an esteemed neurosurgeon and professor conducting research on deep brain stimulation. She was hooked; following a PhD in neurobiology and a post doc at the University of Chicago, Buggia-Prevot joined MD Anderson’s Neurodegeneration Consortium, managing strategic alliances and working on drug discovery. In November, she joined Valo as director of neurology discovery, an opportunity to bring new research in neurodegeneration to bear on patients’ lives.
You may also be interested in...
Biogen’s Aducanumab Falls Hard At Panel Review, Leaving US FDA In A Tight Spot
Successful EMERGE trial does not provide substantial evidence of efficacy in Alzheimer’s because it cannot be divorced from its unsuccessful sister study, advisory committee says; panel’s unequivocal rejection leaves agency’s Office of Neuroscience in a tight spot given its strong support for the drug and the help it gave Biogen to get this far.
Carving Out New Spaces In Cancer Immunotherapy
With a combined $335m raised in a crossover series B funding and an IPO last summer, Cambridge, MA-based iTeos Therapeutics has the juice to move its two cancer immunotherapy clinical programs forward.
SPACs Surge In 2020
Despite the COVID-19 chaos felt by many industries in 2020, biopharma IPOs recorded a banner year – including a marked rise in the use of special purpose acquisition companies (SPACs), also known as blank check companies.
Need a specific report? 1000+ reports available
Buy Reports